Ventyx Biosciences (VTYX)
(Real Time Quote from BATS)
$2.10 USD
-0.14 (-6.25%)
Updated Aug 2, 2024 02:54 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Price, Consensus and EPS Surprise
VTYX 2.10 -0.14(-6.25%)
Will VTYX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VTYX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VTYX
What Makes Ventyx Biosciences (VTYX) a New Buy Stock
Down -86.57% in 4 Weeks, Here's Why Ventyx Biosciences, Inc. (VTYX) Looks Ripe for a Turnaround
VTYX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ventyx (VTYX) Down Despite Positive Ulcerative Colitis Study Data
Take the Zacks Approach to Beat the Market: Uber, Baidu, AssetMark in Focus
Recent Price Trend in Ventyx Biosciences, Inc. (VTYX) is Your Friend, Here's Why
Other News for VTYX
Ventyx Biosciences: Hold Rating Affirmed Amid Clinical and Strategic Setbacks
Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Participants with Moderately to Severely Active Crohn?s Disease
Ventyx Biosciences falls after trial for Crohn’s disease treatment did not meet main goal
Ventyx Biosciences announces reuslts from Phase 2 trial of VTX958
Ventyx falls 19% to $2.39 after Crohn's disease trial misses endpoint